TYK2 as a novel therapeutic target in psoriasis.

Sarah ElyoussfiShraddha S RaneSteve EyreRichard Bruce Warren

Published in: Expert review of clinical pharmacology (2023)

The TYK2 inhibitor deucravacitinib shows promise as an effective oral agent for treating psoriasis. Longer term data are needed to know if thrombotic risk/cancer risk is distinct from other Janus kinase (JAK) inhibitors. Psoriasis is a complex genetic disease for which risk is influenced by genes and environmental factors. GWAS studies have identified several regions of DNA associated with increased risk of disease. We believe that pathway analysis by genetic and genomic means will be key to optimizing TYK2 therapy for the right person at the right time.

Keyphrases

genome wide
copy number
electronic health record
preterm infants
atopic dermatitis
machine learning
dna methylation
deep learning
tyrosine kinase
gene expression
transcription factor